HEIMSBRUNN, France, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Group FH ORTHO, a global leader in orthopedic prosthetic technologies, ...

ProDentim enters the spotlight at a time when more individuals are rethinking conventional dental products, questioning the ...

“Partnering with GreenBe Pharma propels our mission to increase global accessibility to premium cannabis genetics,” said Jamie Blundell, CEO of Segra International. “This alliance underscores our ...

Since initiation of the program, the following transactions have been made: The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

The Company also announced today that the TSXV has granted an extension to the deadline for the completion of the Offering to February 17, 2025. The Company anticipates having an additional closing of ...

“We’re pleased to complete the acquisition and add two new territories in Nova Scotia,” said Dana Hatfield, Chair of the Board of Nova Leap. “We are looking forward to working with the existing ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

This initiative is part of KFSHRC's efforts to foster innovation in healthcare, ensuring a reduction in the prevalence of genetic disorders and improving quality of life. It also reinforces the ...

Following the successful launch of its GLP Compass (™), Digbi Health continues to innovate by expanding its obesity test capabilities in 2025. These enhancements guide care providers and benefit ...

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded ...